NasdaqCM - Nasdaq Real Time Price USD

DataMEDS AI, Inc. (MEDS)

1.0101 -0.1699 (-14.40%)

As of 2:05:58 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

DataMeds AI Signs Preliminary Agreement With Florida Health Insurer for GLP-1 Patient Management App

InvestorsHub 4d ago

MEDS
-14.40%
DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee Recommendations

InvestorsHub 7d ago

MEDS
-14.40%
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network

ACCESS Newswire 17d ago

MEDS
-14.40%
DataMeds Regains Compliance With NASDAQ Listing Standards

ACCESS Newswire 20d ago

MEDS
-14.40%
DVLT
DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal

InvestorsHub 24d ago

MEDS
-14.40%
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

ACCESS Newswire 24d ago

MEDS
-14.40%
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

ACCESS Newswire 26d ago

MEDS
-14.40%
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

InvestorsHub 27d ago

MEDS
-14.40%
HUM
DataMeds AI Announces Workforce Reductions as It Prioritises ChemoFx Cancer Diagnostic Test Commercialisation

InvestorsHub 27d ago

MEDS
-14.40%
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

ACCESS Newswire 27d ago

MEDS
-14.40%
HUM
DataMeds AI Secures Medicaid Coverage for ChemoFx Assay in Gynecologic Cancers

InvestorsHub 28d ago

MEDS
-14.40%
HUM
DataMeds AI Corexa Pharmacy Surpasses $1 Million in Monthly Revenue as Sales Rise 66%

InvestorsHub 1mo ago

MEDS
-14.40%

Performance Overview

Return	MEDS	S&P 500 (^GSPC)
YTD	-94.90%	+10.34%
1-Year	-96.81%	+12.25%
3-Year	-99.53%	+73.74%

U.S. markets close in 1h 51m

DataMEDS AI, Inc. (MEDS)

DataMeds AI Signs Preliminary Agreement With Florida Health Insurer for GLP-1 Patient Management App

DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee Recommendations

DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network

DataMeds Regains Compliance With NASDAQ Listing Standards

DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

DataMeds AI Announces Workforce Reductions as It Prioritises ChemoFx Cancer Diagnostic Test Commercialisation

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

DataMeds AI Secures Medicaid Coverage for ChemoFx Assay in Gynecologic Cancers

DataMeds AI Corexa Pharmacy Surpasses $1 Million in Monthly Revenue as Sales Rise 66%